GlobeNewsWire
31 May 2026, 23:30 UTC · 3h ago
Source · https://www.globenewswire.com/news-release/2026/05/31/3303964/0/en/Ascentage-Pharma-Presents-Data-on-Olverembatinib-in-CML-LBP-and-Ph-BCP-ALL-at-ASCO-2026.html
Read source
Story key points
4 claims · impact-rated
Phase Ib study results for olverembatinib combined with blinatumomab showed encouraging clinical activity and strong response rates in patients with relapsed/refractory Ph+ BCP-ALL or CML-LBP. — Positive clinical data in difficult-to-treat cancer indications typically drives significant upward valuation for biotech firms.
+0.60Ascentage Pharma is conducting three global registrational Phase III studies for olverembatinib, with two cleared by the FDA and EMA. — Progression to Phase III and regulatory clearance in major Western markets increases the probability of future commercial approval and revenue.
+0.50Takeda holds an exclusive option agreement to license the global rights for olverembatinib outside of Greater China. — A potential partnership with a major pharmaceutical company like Takeda provides a significant non-dilutive funding path and commercial validation.
+0.40Continue reading
6 related stories
Search tags
The combination therapy was reported as generally well tolerated with a safety profile consistent with individual agent toxicities. — Lack of unexpected toxicity reduces the risk of clinical hold or regulatory rejection, supporting the drug's path to market.
+0.30Ticker attribution
Model heads
The company presented encouraging Phase Ib clinical data and rapid oral presentations at the ASCO 2026 meeting for its core product olverembatinib.
Takeda holds an exclusive option agreement to license and commercialize olverembatinib globally outside of Greater China.
Innovent Biologics is jointly commercializing olverembatinib in China, benefiting from the drug's approvals and positive clinical data.
Impact vectors
6 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
3h ago
